Aelis Farma SA (FR:AELIS)
:AELIS
Want to see FR:AELIS full AI Analyst Report?
AELIS Stock Chart & Stats
€1.15
€0.07(3.63%)
At close: 4:00 PM EST
€1.15
€0.07(3.63%)
Day’s Range― - ―
52-Week Range€0.67 - €2.30
Previous CloseN/A
Volume1.12K
Average Volume (3M)48.51K
Market Cap
€15.27M
Enterprise Value€15.57M
Total Cash (Recent Filing)€8.21M
Total Debt (Recent Filing)€6.60M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Sep 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding13,706,586
10 Day Avg. Volume44,132
30 Day Avg. Volume48,508
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)3.49
Price to Sales (P/S)7.43
P/FCF Ratio-2.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.17
Revenue Forecast (FY)€12.40M
Bulls Say, Bears Say
Bulls Say
Focused R&D And Partnering ModelAelis Farma’s business model prioritizes early-stage R&D and partnering over capital-intensive commercialization. This durable model can limit long-term fixed costs, allow risk sharing via collaborations or licensing, and preserve upside from clinical successes while avoiding the structural burdens of a full commercial organization.
Lean Operating FootprintA small headcount suggests a lean, focused organization typical of clinical-stage specialty biotechs. This reduces recurring payroll and infrastructure costs, enabling concentrated R&D spend on core candidates and extending runway per euro of financing compared with larger, commercial-stage peers.
Signs Of Improving Cash Outflow TrendsOperating cash outflow halving year-over-year indicates management has begun to slow burn, a meaningful operational improvement. If sustained through tighter expense control or milestone receipts, this trend can materially reduce near-term financing needs and lower dilution risk over the coming months.
Bears Say
Persistent Negative Cash FlowMulti-year negative operating and free cash flow shows the company continues to consume cash to fund R&D. This enduring burn requires external financing or partnerships to sustain development, increasing execution and dilution risk if clinical progress or funding sources do not materialize.
Sustained Losses And Deteriorating MarginsMaterial negative margins and recurring losses indicate the current cost base is unsupported by revenues. Without a clear pathway to material revenue or substantial cost restructuring, profitability is unlikely in the medium term, pressuring capital needs and strategic flexibility.
Eroding Equity And Capital CushionA shrinking equity base alongside rising debt weakens the balance sheet and reduces the firm’s ability to absorb setbacks. Historical swings (including past negative equity) highlight recurring recapitalization risk, making long-term funding and dilution risk structural concerns for investors.
Aelis Farma SA News
AELIS FAQ
What was Aelis Farma SA’s price range in the past 12 months?
Aelis Farma SA lowest stock price was €0.67 and its highest was €2.30 in the past 12 months.
What is Aelis Farma SA’s market cap?
Aelis Farma SA’s market cap is €15.27M.
When is Aelis Farma SA’s upcoming earnings report date?
Aelis Farma SA’s upcoming earnings report date is Sep 15, 2026 which is in 94 days.
How were Aelis Farma SA’s earnings last quarter?
Aelis Farma SA released its earnings results on Mar 30, 2026. The company reported -€0.154 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.154.
Is Aelis Farma SA overvalued?
According to Wall Street analysts Aelis Farma SA’s price is currently Overvalued.
Does Aelis Farma SA pay dividends?
Aelis Farma SA does not currently pay dividends.
What is Aelis Farma SA’s EPS estimate?
Aelis Farma SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aelis Farma SA have?
Aelis Farma SA has 13,706,586 shares outstanding.
What happened to Aelis Farma SA’s price movement after its last earnings report?
Aelis Farma SA reported an EPS of -€0.154 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.575%.
Which hedge fund is a major shareholder of Aelis Farma SA?
Currently, no hedge funds are holding shares in FR:AELIS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aelis Farma SA
Aelis Farma S.A., a French biotechnology company founded in 2013 and headquartered in Bordeaux, is dedicated to the discovery and development of treatments for brain-related illnesses. The firm's research pipeline primarily focuses on signaling-specific inhibitors that target CB1 receptors. Its leading investigational drug, AEF0117, is currently advancing through Phase 2b clinical trials, designed to alleviate the harmful impacts of excessive cannabis consumption. Furthermore, AEF0217, another key drug candidate, has successfully completed Phase 1 clinical trials, with the goal of addressing cognitive impairments linked to Down syndrome and other similar conditions.
Technical Analysis
Poxel SA
―
GenSight Biologics SA
―
Advicenne SA
―
Biophytis SA
―
NFL Biosciences SA
―